Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EPS (Weighted Average and Diluted) (2016 - 2025)

Regenxbio (RGNX) has 10 years of EPS (Weighted Average and Diluted) data on record, last reported at -$1.3 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 30.0% year-over-year to -$1.3; the TTM value through Dec 2025 reached -$3.76, up 18.08%, while the annual FY2025 figure was -$3.76, 18.08% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.3 in Q4 2025 per RGNX's latest filing, down from -$1.2 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $6.84 in Q4 2021 and bottomed at -$1.79 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.88, with a median of -$1.38 recorded in 2024.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 651.61% in 2021, down 695.65% in 2021.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $6.84 in 2021, then tumbled by 120.32% to -$1.39 in 2022, then fell by 2.16% to -$1.42 in 2023, then grew by 29.58% to -$1.0 in 2024, then dropped by 30.0% to -$1.3 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$1.3 in Q4 2025, -$1.2 in Q3 2025, and -$1.38 in Q2 2025.